Antiva Biosciences

Executive Summary

Antiva Biosciences is a clinical-stage biopharmaceutical company focused on developing novel topical therapeutics for high-risk human papillomavirus (HPV) infections and the pre-cancerous cervical lesions they cause. Founded in 2012 and based in San Francisco, the company aims to provide a non-invasive, self-administered alternative to current surgical procedures, aligning with global efforts to eliminate cervical cancer through early intervention. Antiva's lead candidate is in Phase 1 development, targeting the substantial unmet need for effective topical treatments in HPV-related disease. The company's approach could significantly improve patient compliance and accessibility compared to standard-of-care surgical options. As a private company, Antiva is well-positioned to address a large market opportunity, though it remains in early clinical stages with limited public data. The company continues to advance its pipeline, leveraging its expertise in topical formulations for mucosal applications.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lead compound70% success
• H1 2027Partnership or licensing deal for development or commercialization50% success
• Q2 2027Expansion of pipeline to additional HPV-related indications60% success